Tumor antigen, dendritic cell tumor vaccine, preparation method and pharmaceutical composition

By inhibiting the MSI1 gene expression and stress treatment of tumor cells, tumor antigens containing a large number of damage-related model molecules were prepared to prepare dendritic cell tumor vaccines, which solved the problem of poor maturity of immune cells in existing tumor vaccines. It significantly improved the treatment effect, extended the survival time of mice and inhibited tumor growth.

CN119060157APending Publication Date: 2024-12-03洪明奇
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310638666.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-06-01
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

Due to the stress-resistant treatment mechanism of tumor cells, existing tumor vaccines have poor maturity and poor treatment effect.

Method used

By inhibiting the MSI1 gene expression of tumor cells and performing pressure treatment to increase the expression of damage-related model molecules, tumor antigens containing a large number of damage-related model molecules were prepared, which is used to prepare dendritic cell tumor vaccines and improve dendritic cell Maturity and therapeutic effect.

Benefits of technology

It significantly improved the therapeutic effect of dendritic cell tumor vaccine, enhanced the immune response, extended the survival time of mice in animal models, and effectively inhibited the growth of various types of tumors.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119060157A_ABST
    Figure CN119060157A_ABST
Patent Text Reader

Abstract

The invention provides a tumor antigen and a preparation method thereof. The tumor antigen is prepared by the following steps. And providing a tumor tissue specimen, and performing primary isolation and culture on the tumor tissue specimen to obtain tumor cells. The expression of the MSI1 gene of the tumor cell is inhibited by an inhibition method so as to obtain the inhibited tumor cell. And treating the inhibited tumor cells by a pressure treatment method, and then performing a cell lysis step to obtain the tumor antigen. Therefore, by inhibiting the expression of the MSI1 gene of the tumor cells and then carrying out pressure treatment, the obtained tumor antigen contains a large number of damage-related mode molecules and can be subsequently used for preparing the dendritic cell tumor vaccine. The dendritic cells in the prepared dendritic cell tumor vaccine are better in maturity, and the treatment effect of the dendritic cell tumor vaccine is improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a tumor antigen, a preparation method thereof, a dendritic cell tumor vaccine, a preparation method thereof and a pharmaceutical composition for treating cancer, and in particular to a tumor antigen that inhibits the expression of tumor cell stress resistance genes, a preparation method thereof, a dendritic cell tumor vaccine, a preparation method thereof and a pharmaceutical composition for treating cancer. Background Art

[0002] Cancer, also known as malignant tumor, is an abnormal proliferation of cells that may invade other parts of the body. It is a disease caused by the abnormal control of cell division and proliferation. The number of people suffering from cancer in the world is increasing. Cancer is one of the top ten causes of death in China and has been ranked first for 27 consecutive years.

[0003] Conventional tumor treatment methods include surgery, radiotherapy, and chemotherapy. Tumor vaccines are another method of treating tumors besides the above treatment methods. They activate the patient's own immune system, use tumor cells or tumor antigens to induce the body's specific cellular and humoral immune responses, enhance the body's anti-cancer ability, and prevent tumor growth, spread, and recurrence, so as to achieve the purpose of eliminating or controlling tumors.

[0004] Tumor vaccines in the prior art all target tumor cells, and the tumor cells are subjected to pressure treatment and the antigens obtained by lysing the tumor cells are then loaded onto immune cells. However, since tumor cells have mechanisms to resist pressure treatment, such as radiation irradiation or chemotherapy drug treatment, the tumor vaccines obtained in this way are often used to treat cancer, but the treatment effect is poor due to the poor maturity of the immune cells in the tumor vaccines. Therefore, how to provide a tumor antigen that can effectively enhance the maturity of immune cells to improve the therapeutic effect of the prepared tumor vaccine has become a problem to be solved. Summary of the invention

[0005] In view of this, one purpose of the present invention is to propose a specially treated tumor antigen, which inhibits the expression of stress resistance genes in tumor cells and then undergoes pressure treatment to obtain a tumor antigen containing a large number of damage-related pattern molecules, which can be subsequently used to prepare dendritic cell tumor vaccines to induce a strong immune response of dendritic cells.

[0006] Another object of the present invention is to propose a dendritic cell tumor vaccine with excellent therapeutic effect. The dendritic cell tumor vaccine is prepared using a tumor antigen containing a large number of damage-related pattern molecules, which can make the dendritic cells therein more mature and improve the therapeutic effect of the dendritic cell tumor vaccine, so as to solve the problem of poor therapeutic effect caused by poor maturity of immune cells in the tumor vaccine.

[0007] One aspect of the present invention is to provide a method for preparing a tumor antigen, comprising: providing a tumor tissue specimen, performing an inhibition step, performing a pressure treatment step, and performing a cell lysis step. After providing the tumor tissue specimen, the tumor tissue specimen is primary isolated and cultured to obtain tumor cells. The inhibition step is to inhibit the expression of the MSI1 gene of the tumor cells by an inhibition method to obtain suppressed tumor cells. The pressure treatment step is to treat the suppressed tumor cells by a pressure treatment method so that the damage associated molecular patterns (DAMP) genes of the suppressed tumor cells are expressed in large quantities to obtain pressure-treated tumor cells. The cell lysis step is to treat the pressure-treated tumor cells by a cell disruption method to obtain tumor antigens.

[0008] According to the aforementioned method for preparing tumor antigens, the inhibition method may be gene knockdown, gene knockout, chemical inhibitors or a combination thereof.

[0009] According to the aforementioned method for preparing tumor antigens, the gene inhibition method can use a short interfering RNA (siRNA) to inhibit the expression of the MSI1 gene in tumor cells, and the short interfering RNA can be the sequence shown in SEQ ID NO: 1, the sequence shown in SEQ ID NO: 2, the sequence shown in SEQ ID NO: 3, the sequence shown in SEQ ID NO: 4, or a combination thereof.

[0010] According to the aforementioned method for preparing tumor antigens, the pressure treatment method may be radiation irradiation treatment, UV irradiation treatment, hypoxia treatment, chemotherapeutic drug treatment, chemical agent treatment or a combination thereof.

[0011] According to the above-mentioned method for preparing tumor antigens, when the pressure treatment method is radiation irradiation treatment, the radiation dose can be 10 Gy to 30 Gy. When the pressure treatment method is UV irradiation treatment, 100 J / cm 2 The inhibited tumor cells are irradiated with UVC radiation. When the pressure treatment method is hypoxia treatment, the inhibited tumor cells can be cultured under the condition of 1% oxygen content for 16 hours.

[0012] According to the aforementioned method for preparing tumor antigens, the damage-related pattern molecule genes may include HMG family genes, HSP70 family genes, HSP90 family genes and S100 family genes. Further, the damage-related pattern molecule genes may include HMGB1 gene, HMGB2 gene, HMGN1 gene, HSP90AA1 gene, HSP90AB1 gene, HSP90B1 gene, HSPA1B gene, HSPA5 gene, HSPA1A gene, S100A11 gene, S100A10 gene, S100A13 gene, S100A4 gene, S100A2 gene, BSG gene, TLR4 gene, CALR gene, SRA1 gene, LRP1 gene, BCL2 gene and IL1R1 gene.

[0013] According to the aforementioned method for preparing tumor antigens, the cell disruption method can be freeze-thaw disruption, osmotic pressure impact disruption, high-pressure homogenization disruption, oscillating bead beating disruption, high-speed stirring bead grinding disruption or ultrasonic disruption.

[0014] Another aspect of the present invention is to provide a tumor antigen, which is prepared using the above-mentioned method for preparing a tumor antigen.

[0015] Another aspect of the present invention is to provide a method for preparing a dendritic cell tumor vaccine, comprising: providing the aforementioned tumor antigen, isolating dendritic cells, and performing a co-culture step. The co-culture step is to co-culture the dendritic cells with the tumor antigen to obtain the dendritic cell tumor vaccine.

[0016] According to the aforementioned method for preparing a dendritic cell tumor vaccine, the dendritic cells may be autologous dendritic cells or allogeneic dendritic cells.

[0017] Another aspect of the present invention is to provide a dendritic cell tumor vaccine, which is prepared using the above-mentioned method for preparing the dendritic cell tumor vaccine.

[0018] Another aspect of the present invention is to provide a pharmaceutical composition for treating cancer, comprising the above-mentioned dendritic cell tumor vaccine and a pharmaceutically acceptable carrier.

[0019] The aforementioned pharmaceutical composition for treating cancer may further comprise T cells.

[0020] The aforementioned pharmaceutical composition for treating cancer may further comprise chemotherapeutic drugs, targeted therapeutic drugs, antibody drugs, immunomodulators or a combination thereof.

[0021] The above summary is intended to provide a simplified summary of the present disclosure so that readers can have a basic understanding of the present disclosure. This summary is not a complete overview of the present disclosure and is not intended to point out the important / critical elements of the embodiments of the present invention or to define the scope of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS

[0022] In order to make the above and other objects, features, advantages and embodiments of the present invention more clearly understood, the following are the descriptions of the accompanying drawings:

[0023] Figure 1A A flowchart showing the steps of a method for preparing a tumor antigen according to one embodiment of the present invention is shown;

[0024] Figure 1B A flowchart showing the steps of a method for preparing a dendritic cell tumor vaccine according to another embodiment of the present invention;

[0025] Figure 2 This is a diagram showing the analysis results of the target genes regulated by MSI1 protein using RIP-Seq;

[0026] Figure 3A and Figure 3B The results of the analysis of siMSI1 inhibiting the expression of MSI1 protein in the human brain glioma cell line 05MG and the mouse brain glioma cell line GL261-Luc;

[0027] Figure 4A and Figure 4B This is a graph showing the analysis results of the expression of damage-related pattern molecules in tumor antigens treated with radiation;

[0028] Figure 5A and Figure 5B This is a graph showing the analysis results of the expression of damage-related pattern molecules in tumor antigens treated with UV irradiation;

[0029] Fig. 6A and Figure 6B This is a diagram showing the analysis results of the expression of damage-related pattern molecules in tumor antigens treated with hypoxia;

[0030] Fig. 7A , Figure 7B and Figure 7C This is a diagram showing the analysis results of the therapeutic effect of the dendritic cell tumor vaccine of the present invention on orthotopic brain tumor model mice;

[0031] Fig. 8A and Figure 8B This is a diagram showing the analysis results of the tumor cell killing ability of the pharmaceutical composition for treating cancer of the present invention;

[0032] Fig. 9A , Fig. 9B , Fig. 9C, Fig.9D , Fig.9E and Fig.9F CD4 + T cells and CD8 + The results of the analysis of T cell activation are shown in Figure 2.

[0033] Fig. 10A , Fig. 10B , Fig. 10C and Fig. 10D This is a diagram showing the analysis results of the therapeutic effect of the dendritic cell tumor vaccine of the present invention on orthotopic melanoma model mice;

[0034] Fig.11A , Fig. 11B and Fig. 11C The figure is a result of analyzing the therapeutic effect of the dendritic cell tumor vaccine of the present invention on orthotopic breast cancer model mice; and

[0035] Fig.12 The figure is a schematic diagram illustrating the mechanism of action of the pharmaceutical composition for treating cancer of the present invention.

[0036] Wherein, the reference numerals are:

[0037] 100: Method for preparing tumor antigens

[0038] 110,120,130,140: Steps

[0039] 200: Preparation of dendritic cell tumor vaccine

[0040] 210,220,230: Steps DETAILED DESCRIPTION

[0041] Unless otherwise specified, all technical terms, symbols or other scientific terms or terms used in this specification have the meanings commonly known to those skilled in the art in the field to which the present invention belongs. In some cases, terms with commonly known meanings are defined in this specification for the purpose of clarity and / or immediate reference, and these definitions included in this specification should be interpreted as not necessarily having substantial differences from the meanings commonly known in the art. Many of the techniques and procedures described or cited in this specification are well known to the public and are often used by those skilled in the art in conventional methods. Where appropriate, unless otherwise specified, the use procedures of commercially available kits and reagents are generally carried out according to the instructions and / or parameters defined by the manufacturer.

[0042] In this specification, gene names are represented by italic letters, the symbol format of their RNA is the same as that of the gene, and proteins related to the gene are represented by non-italic letters.

[0043] The following are the specific terms used in this manual:

[0044] The term "individual" or "patient" as used herein refers to an animal that can receive the dendritic cell tumor vaccine and / or the pharmaceutical composition for treating cancer of the present invention. In a preferred embodiment, the animal is a mammal.

[0045] The "cancer" described in this specification may be a non-solid tumor or a solid tumor. For example, the cancer includes, but is not limited to, blood cancer, lymphoma, bone sarcoma, multiple myeloma, testicular cancer, thyroid cancer, prostate cancer, pharyngeal cancer, cervical cancer, nasopharyngeal cancer, breast cancer, colorectal cancer, pancreatic cancer, head and neck cancer, esophageal cancer, rectal cancer, lung cancer, liver cancer, brain cancer, malignant brain cancer, melanoma or skin cancer.

[0046] The term "treatment" as used herein refers to administering the pharmaceutical composition of the present invention to a subject in need thereof, such as a cancer patient.

[0047] The term "improvement" as used herein means to reduce, inhibit, weaken, diminish, stop or stabilize the development or progression of a disease or its symptoms.

[0048] The "damage associated molecular patterns (DAMPs)" mentioned in this specification are a type of soluble molecules released by damaged cells when the body cells are subjected to stress changes, which can trigger an inflammatory response.

[0049] The "MSI1 (Musashi-1) gene" described in this specification is a gene encoding the MSI1 protein. The MSI1 protein is a nucleic acid binding protein that plays a key role in a variety of cells, such as maintaining stem cell self-renewal and pluripotency. It affects the proliferation and differentiation of precursor stem cells and stem cells by regulating p21, Notch, and Wnt, and is a marker molecule for neural stem cells. In recent years, it has been found that the expression of the MSI1 protein increases in colorectal cancer, rectal cancer, breast cancer, and malignant brain tumors, indirectly regulating the cell cycle, inhibiting cell apoptosis, affecting the excessive proliferation and survival of tumors, and increasing the drug resistance and survival rate of brain tumors. In addition, the MSI1 protein is also considered a marker for metastatic cancer or recurrent tumors.

[0050] The "cold tumor (immunogenic cold tumor)" and "hot tumor (immunogenic hot tumor)" described in this specification are distinguished by whether the tumor tissue is easy to attract immune cells. Cold tumors refer to non-immunogenic tumors, that is, there are no or very few immune cells in the tumor tissue, while hot tumors refer to immunogenic tumors, that is, a lot of immune cells have gathered around and near the tumor tissue. Hot tumors usually have a high mutation burden (tumor mutation burden, TMB), because there are many changes in DNA coding, causing tumor cells to produce unique new molecules called "neoantigens" on their cell surfaces. These new antigens make tumors easier to be recognized by the immune system and are therefore more likely to cause a strong immune response. In contrast, cold tumors are cancers that are not recognized or do not cause a strong immune response for various reasons. Immune T cells can no longer recognize such tumors, and the microenvironment inside and around tumor cells includes blood vessels, structural elements and special immune cells (including bone marrow-derived suppressor cells and regulatory T cells), which reduce the response of normal immune responses by secreting immunosuppressive chemical messengers such as cytokines that hinder T cells from entering the tumor, resulting in the surrounding area of ​​the tumor being like an immune desert.

[0051] The present invention is further illustrated by the following specific test examples, which are used to facilitate those with common knowledge in the technical field to which the present invention belongs, so that the present invention can be fully utilized and practiced without excessive interpretation. These test examples should not be regarded as limiting the scope of the present invention, but are used to illustrate how to implement the materials and methods of the present invention.

[0052] [Tumor antigen of the present invention and method for preparing the same]

[0053] Please refer to Figure 1A , which is a flow chart showing the steps of the method 100 for preparing a tumor antigen of the present invention. The method 100 for preparing a tumor antigen comprises step 110, step 120, step 130 and step 140.

[0054] Step 110 is to provide a tumor tissue specimen, and to perform primary separation and culture on the tumor tissue specimen to obtain tumor cells. The tumor tissue specimen may be a non-solid tumor or a solid tumor. For example, it may be a tumor caused by the following cancers, including but not limited to blood cancer, lymphoma, diaphyseal osteosarcoma, multiple myeloma, testicular cancer, thyroid cancer, prostate cancer, pharyngeal cancer, cervical cancer, nasopharyngeal cancer, breast cancer, colorectal cancer, pancreatic cancer, head and neck cancer, esophageal cancer, rectal cancer, lung cancer, liver cancer, brain cancer, malignant brain cancer, melanoma or skin cancer.

[0055] Step 120 is to perform an inhibition step, wherein the expression of the MSI1 gene of the tumor cell is inhibited by an inhibition method to obtain an inhibited tumor cell. The inhibition method may be inhibition by gene knockdown, gene knockout, chemical inhibitors or a combination thereof, such as inhibiting gene expression or performing gene knockout by RNA interference (RNAi) technology or CRISPR technology, wherein RNA interference technology may utilize short interfering RNA (siRNA), small hairpin RNA (shRNA) or micro RNA (miRNA) to achieve the purpose of effectively silencing or inhibiting the expression of the target gene. Further, the siRNA may be a sequence shown in SEQ ID NO: 1, a sequence shown in SEQ ID NO: 2, a sequence shown in SEQ ID NO: 3, a sequence shown in SEQ ID NO: 4 or a combination thereof.

[0056] Step 130 is a pressure treatment step, in which the suppressed tumor cells are treated with a pressure treatment method to cause the damage-related pattern molecule genes of the suppressed tumor cells to be expressed in large quantities, so as to obtain the pressure-treated tumor cells. The pressure treatment method can be radiation irradiation treatment, UV irradiation treatment, hypoxia treatment, chemotherapy drug treatment, chemical agent treatment or a combination thereof. When the pressure treatment method is radiation irradiation treatment, the radiation dose can be 10Gy to 30Gy. When the pressure treatment method is UV irradiation treatment, the UV irradiation condition can be 100J / cm 2 The inhibited tumor cells are irradiated with UVC radiation. When the pressure treatment method is hypoxia treatment, the hypoxia condition can be that the inhibited tumor cells are cultured under the condition of 1% oxygen content for 16 hours.

[0057] The damage-related pattern molecule genes may include HMG family genes, HSP70 family genes, HSP90 family genes and S100 family genes. Further, the damage-related pattern molecule genes may include HMGB1 gene, HMGB2 gene, HMGN1 gene, HSP90AA1 gene, HSP90AB1 gene, HSP90B1 gene, HSPA1B gene, HSPA5 gene, HSPA1A gene, S100A11 gene, S100A10 gene, S100A13 gene, S100A4 gene, S100A2 gene, BSG gene, TLR4 gene, CALR gene, SRA1 gene, LRP1 gene, BCL2 gene and IL1R1 gene.

[0058] Step 140 is a cell lysis step, in which the pressure-treated tumor cells are treated by a cell disruption method to obtain tumor antigens. The cell disruption method may be a mechanical method or a non-mechanical method, such as freezing and thawing, osmotic shock, high-pressure homogenization, shaking beads, fine grinding, or ultrasonication.

[0059] Thus, the method 100 for preparing tumor antigens of the present invention suppresses the expression of the MSI1 gene of tumor cells and then performs pressure treatment. The obtained tumor antigens contain a large number of damage-related pattern molecules and can be subsequently used to prepare dendritic cell tumor vaccines to induce a strong immune response of the dendritic cells therein.

[0060] [Dendritic cell tumor vaccine of the present invention, preparation method thereof and pharmaceutical composition for treating cancer]

[0061] Please refer to Figure 1B , which is a flow chart showing the steps of a method 200 for preparing a dendritic cell tumor vaccine according to another embodiment of the present invention. The method 200 for preparing a dendritic cell tumor vaccine comprises step 210, step 220 and step 230.

[0062] Step 210 is to provide a tumor antigen, which is the tumor antigen prepared through the aforementioned steps 110 to 140 .

[0063] Step 220 is to separate dendritic cells. The dendritic cells may be autologous dendritic cells or allogeneic dendritic cells.

[0064] Step 230 is a co-culture step, in which dendritic cells are co-cultured with tumor antigens to obtain a dendritic cell tumor vaccine.

[0065] Thus, the dendritic cell tumor vaccine preparation method 200 of the present invention uses a tumor antigen containing a large number of damage-related pattern molecules to prepare a dendritic cell tumor vaccine, which can make the dendritic cells therein more mature and improve the therapeutic effect of the dendritic cell tumor vaccine. In addition, the dendritic cell tumor vaccine of the present invention can be prepared using autologous dendritic cells, which has low immune rejection for future treatment, and the comprehensiveness and specificity of immunity are also better than tumor vaccines that do not use autologous dendritic cells, which is a very promising tumor treatment method.

[0066] Furthermore, the present invention further provides a pharmaceutical composition for treating cancer, which comprises the dendritic cell tumor vaccine of the present invention and a pharmaceutically acceptable carrier. In addition, the pharmaceutical composition for treating cancer of the present invention may further comprise T cells, wherein the T cells are mixed and cultured with the dendritic cell tumor vaccine for 24 hours to obtain a pharmaceutical composition for treating cancer. The pharmaceutical composition for treating cancer may further comprise chemotherapeutic drugs, targeted therapeutic drugs, antibody drugs, immunomodulators or a combination thereof, depending on the different conditions of the patient, to achieve a better therapeutic effect.

[0067] [Test example]

[0068] Before preparing tumor antigens, the target genes regulated by MSI1 protein were isolated using RIP-Seq technology. RIP-Seq is a combination of RNA-binding protein immunoprecipitation (RIP) and next-generation sequencing (NGS) analysis. The RNA ChIP-ITKit (Active Motif) was used in the experiment to separate and purify the mRNA of genes that bind to MSI1 protein in cells according to the instructions. After confirming the integrity and quality of the RNA, NGS analysis was performed, and the expression (FPKM) of genes related to cell stress or damage was quantified and integrated.

[0069] Please refer to Figure 2 , is the analysis result of target genes regulated by MSI1 protein by RIP-Seq. Figure 2 The results showed that multiple gene families of damage-related pattern molecules are the targets of MSI1 regulation, including HMG family genes, HSP70 family genes, HSP90 family genes and S100 family genes. Further, the damage-related pattern molecule genes include HMGB1 gene, HMGB2 gene, HSP90AA1 gene, BSG gene, S100A11 gene, S100A10 gene, HMGN1 gene, S100A13 gene, TLR4 gene, HSP90AB1 gene, CALR gene, HSP90B1 gene, S100A4 gene, SRA1 gene, HSPA1B gene, HSPA5 gene, LRP1 gene, BCL2 gene, HSPA1A gene, IL1R1 gene and S100A2 gene.

[0070] 1. Preparation of Tumor Antigens

[0071] The following test examples will demonstrate with data that the dendritic cell tumor vaccine of the present invention and the pharmaceutical composition for treating cancer comprising the dendritic cell tumor vaccine of the present invention have excellent therapeutic effects on various cancers. For the convenience of verification, tumor cell lines were used instead of tumor tissue specimens to prepare tumor antigens. The tumor cell lines used included human brain glioma cell line 05MG (ATCC#CRL-2020, hereinafter referred to as 05MG cells), human brain glioma cell line U87-MG-Luc (hereinafter referred to as U87-MG-Luc cells), mouse brain glioma cell line GL261-Luc (Bioware Ultra, PerkinElmer, hereinafter referred to as GL261-Luc cells), melanoma cell line B16F10 Red-FLuc (Bioware Brite, PerkinElmer, hereinafter referred to as B16F10 Red-FLuc cells) and breast cancer cell line E0771-Luc (CH3 BioSystems, hereinafter referred to as E0771-Luc cells), which were cultured in Dulbecco's Modified Eagle Medium (DMEM) or RPMI-1640 culture medium (Thermo Fisher Scientific) supplemented with 10% fetal bovine serum albumin (fetal bovine serum albumin). serum), L-glutamine, sodium pyruvate and non-essential amino acids, and cultured at 37°C in a humidified atmosphere containing 5% carbon dioxide.

[0072] When preparing tumor antigens, the aforementioned tumor cell lines are first transfected into mouse tumor cell lines with siRNA (hereinafter referred to as "siMSI1") or shRNA targeting the MSI1 gene by transfection reagent or electroporation to inhibit the expression of the MSI1 gene, further reduce the expression of the MSI1 protein, and confirm the expression of the MSI1 protein by Western blot. The siMSI1 used is the sequence shown in SEQ ID NO: 1 (siMSI1#1), the sequence shown in SEQ ID NO: 2 (siMSI1#2), the sequence shown in SEQ ID NO: 3 (siMSI1#3), the sequence shown in SEQ ID NO: 4 (siMSI1#4), or a mixture of the above four siMSI1s. Each tumor cell line is then treated with different pressure treatment methods, and the experiments use radiation irradiation treatment, UV irradiation treatment, and hypoxia treatment as representatives. When the pressure treatment method is radiation irradiation, 10-30 Gy of ionizing radiation, such as x-rays or gamma rays, is used for irradiation, preferably 20 Gy, and then the culture is continued for 24 hours. When the pressure treatment method is UV irradiation, 100 J / cm 2The tumor cells were irradiated with UVC radiation and then cultured for another 16 hours. When the stress treatment method was hypoxia, the tumor cells were cultured for 16 hours under 1% oxygen content. The cell concentration was then adjusted to 1×10 7 After 6 cycles of freeze-thaw reaction, each reaction was placed in liquid nitrogen for 3 minutes and then placed in a 56°C water bath for 3 minutes. The obtained lysate is the tumor antigen of the present invention. The tumor antigen can be further centrifuged at 500g for 5 minutes, the supernatant is recovered, and stored at -80°C for future use.

[0073] The experiment also includes a comparative tumor antigen, which differs from the tumor antigen of the present invention in that the siRNA or shRNA used is a control group (Scramble control) siRNA (hereinafter referred to as "siCON") or shRNA that does not inhibit any gene of the mouse tumor cell line, and the rest of the preparation process is the same as the tumor antigen of the present invention.

[0074] Please refer to Figure 3A and Figure 3B , which is the analysis result of siMSI1 inhibiting the expression of MSI1 protein in 05MG cells and GL261-Luc cells, wherein siMSI1 represents the group that uses siMSI1#1 to siMSI1#4 to inhibit the expression of MSI1 gene in tumor cells, siMSI1#1 represents the group that uses siMSI1#1 to inhibit the expression of MSI1 gene in tumor cells, and siMSI1#2 represents the group that uses siMSI1#2 to inhibit the expression of MSI1 gene in tumor cells. Figure 3A and Figure 3B The results showed that the use of the above siMSI1 could inhibit the expression of MSI1 protein in 05MG cells and GL261-Luc cells.

[0075] Please refer to 4A to 6B ,in Figure 4A and Figure 4B This is a graph showing the results of analyzing the expression of damage-related pattern molecules in tumor antigens treated with radiation. Figure 5A and Figure 5B This is a graph showing the analysis results of the expression of damage-related pattern molecules in tumor antigens treated with UV irradiation. Fig. 6A and Figure 6B The figure shows the analysis results of the expression levels of damage-related pattern molecules in tumor antigens treated with hypoxia.

[0076] Figure 4AThe results showed that increasing the expression of MSI1 protein (Flag-MSI1) would reduce the production and release of damage-related pattern molecules such as HMGB1, HSP70 and HSP90 after radiotherapy, indicating that the increase in the expression of MSI1 protein would reduce the immunogenic cell death (ICD) of tumor cells. Figure 4B The results showed that if siMSI1 (mixed with siMSI1#1 to siMSI1#4) is used to inhibit the expression of MSI1 gene, it can enhance the expression and release of damage-related pattern molecules after tumor cells are irradiated with radiation, which means that the reduction of MSI1 protein expression can enhance the immunogenic cell death of tumor cells. Figure 5A Figure and Figure 5B The group treated with UV irradiation, and Fig. 6A and Figure 6B The group treated with hypoxia also showed similar results. Inhibition of MSI1 protein can also promote the expression and release of damage-related pattern molecules in tumor cells treated with UV irradiation or hypoxia, indicating that under different stress treatments, reducing the effect of MSI1 protein can effectively enhance the immunogenic cell death of tumor cells and promote the expression and release of damage-related pattern molecules.

[0077] 2. Preparation of Dendritic Cell Tumor Vaccine

[0078] The preparation method of tumor antigen is as described above. In the part of isolating dendritic cells, the femur of C57BL / 6JNarl mice is first surgically removed and immersed in 75% ethanol. The bone marrow cells are washed out from the femur with Hank's balanced salt solution (HBSS), and the red blood cells are removed. The bone marrow cells are then cultured in a dendritic cell culture medium containing 10% fetal bovine serum albumin, glutamine, sodium pyruvate, non-essential amino acids, 20ng / mL mouse recombinant granulocyte macrophage cell line stimulating factor (GM-CSF) and 10ng / mL mouse recombinant interleukin-4 (IL-4). After 4 days of culture, 10mL of fresh dendritic cell culture medium is added to the above culture medium. On the 6th day, the unattached cells, that is, immature dendritic cells, are gently aspirated and co-cultured with 100μg of tumor antigen for 30 minutes. Afterwards, lipopolysaccharides (LPS) were used for differentiation for 24 hours to obtain the dendritic cell tumor vaccine of the present invention, wherein the dendritic cells contained therein were mature dendritic cells. Flow cytometry was then used to analyze that the cells in the dendritic cell tumor vaccine of the present invention could express surface antigens such as CD11c, CD40, CD80 and CD86. The experiment also included a dendritic cell tumor vaccine of a comparative example, which differed from the dendritic cell tumor vaccine of the present invention in that the tumor antigen of the comparative example was used to prepare the dendritic cell tumor vaccine, and the rest of the preparation process was the same as the dendritic cell tumor vaccine of the present invention.

[0079] 3. Cancer Treatment Effect

[0080] 3.1 Animal experiments

[0081] In this experiment, orthotopic brain tumor models, orthotopic melanoma models, and orthotopic breast cancer models were used to verify the cancer treatment effects of the dendritic cell tumor vaccine and the pharmaceutical composition for treating cancer of the present invention. Animal experiments were conducted in accordance with the "Animal Care and Use Procedures" specifications, and the experimental animals were 6-week-old female C57BL / 6JNar1 mice. In order to construct an orthotopic brain tumor model, each C57BL / 6JNar1 mouse was implanted with 2×10 4 In the orthotopic breast cancer model, 2×10 GL261-Luc cells were implanted subcutaneously in the mammary gland of each C57BL / 6JNar1 mouse. 5 In the orthotopic melanoma model, 5×10 E0771-Luc cells were implanted subcutaneously on the back of each C57BL / 6JNar1 mouse. 4B16F10 Red-FLuc cells were implanted in the mice (hereinafter referred to as orthotopic melanoma model mice). The date of implantation is referred to as day 0, and the date of any treatment given to the mice thereafter is referred to as a specific date after day 0. Every week after tumor cell implantation, the size of the tumor in the mouse brain was estimated using an in vivo imaging system (IVIS Spectrum, PerkinElmer). In addition, the survival rate of mice with brain tumors or melanoma was analyzed using Kaplan-Meier survival curves and log-rank tests, and the mean survival time and median survival time after tumor implantation were calculated.

[0082] During the treatment, on the 7th and 14th days after tumor cell implantation, the tumor-bearing mice were subcutaneously injected with the dendritic cell tumor vaccine of the comparative example or the dendritic cell tumor vaccine of the present invention (containing 1×10 6 cells).

[0083] 3.2 The effect of the dendritic cell tumor vaccine of the present invention on the survival rate of mice with orthotopic brain tumor model

[0084] In order to evaluate whether the dendritic cell tumor vaccine of the present invention has a better therapeutic effect on malignant brain tumors than the conventional dendritic cell tumor vaccine, the in situ brain tumor model mice were randomly divided into groups and injected subcutaneously in the groin with the following components: phosphate buffered saline (PBS) as a control group without treatment, a dendritic cell tumor vaccine of the comparative example as a comparative example, and the dendritic cell tumor vaccine of the present invention as an example. Afterwards, each group of mice was observed weekly with a live imaging system to draw a tumor growth curve, and the death time of the mice was recorded to complete the Kaplan-Meier survival curve and calculate the median survival.

[0085] Please refer to FIG. 7A to FIG. 7C , is a diagram showing the analysis of the therapeutic effect of the dendritic cell tumor vaccine of the present invention on orthotopic brain tumor model mice, wherein Fig. 7A This is the in vivo image of the orthotopic brain tumor model mouse on day 28. Figure 7B The tumor growth curve is Figure 7C The figure is the Kaplan-Meier survival curve. Please refer to Table 1 below, which is the median survival of mice with orthotopic brain tumor model.

[0086] Table 1. Median survival of mice in orthotopic brain tumor model

[0087] Group Number (n) Median survival (days) Control Group 4 32 Comparative Example 6 38.5 Example 8 51

[0088] FIG. 7A to FIG. 7CThe results in Table 1 show that the median survival of mice treated with two doses of the comparative dendritic cell tumor vaccine was extended by about 6.5 days (38.5 days vs. 32 days) compared to the untreated orthotopic brain tumor model mice, while the median survival of the orthotopic brain tumor model mice treated with the dendritic cell tumor vaccine of the present invention reached 51 days, and even half of the mice (n=4 / 8) had no residual tumor signals for more than 60 days. This data shows that the dendritic cell tumor vaccine of the present invention can increase the tumor inhibition effect and effectively prolong the survival time of the orthotopic brain tumor model mice.

[0089] 3.3 Pharmaceutical composition for treating cancer comprising T cell culture

[0090] The experiment also explored the mixed lymphocyte culture of isolated and cultured mouse primary cultured T cells and dendritic cell tumor vaccines treated in different ways (comparative example and example) to prepare the pharmaceutical composition for treating cancer of the comparative example and the pharmaceutical composition for treating cancer of the example, and observed the changes in the ability to kill tumor cells.

[0091] In the experiment, the spleen was obtained after the mice were sacrificed, homogenized, treated with red blood cell lysing solution, and centrifuged to separate and purify the splenocytes (lymphocytes in the spleen). The splenocytes were cultured in RPMI-1640 medium containing CD3 / CD28 monoclonal antibodies for 5 days, and mixed with the dendritic cell tumor vaccine of the comparative example and the dendritic cell tumor vaccine of the present invention for 24 hours. At the same time, the tumor cell line expressing the luminescent enzyme was planted in a 96-well culture plate, and after overnight culture, the splenocytes / dendritic cells were added to the tumor cell line for mixed culture. After 6 hours, the suspended cells were removed, the luminescent enzyme substrate (luciferin) was added, and the luminescent signal in each well was measured by a luminescent detection device to quantify the residual and surviving tumor cells.

[0092] Please refer to Fig. 8A and Figure 8B , is a graph showing the analysis result of the tumor cell killing ability of the pharmaceutical composition for treating cancer of the present invention, wherein Fig. 8A This is the analysis result of GL261-Luc cells. Figure 8B The figure shows the analysis results of U87-MG-Luc cells, where TC stands for T cells and DC stands for dendritic cells.

[0093] Fig. 8AThe results showed that the dendritic cell tumor vaccine of the comparative example could slightly enhance the tumor cell killing ability of T cells, but the dendritic cell tumor vaccine of the present invention had a stronger effect. When the mixing ratio of TC and DC was 1:0.1, the tumor cell killing ability of the embodiment increased by 9.4% (74.8% vs. 65.4%) compared with the comparative example; when the mixing ratio of TC and DC was 1:2, the tumor cell killing ability of the embodiment increased by 19.6% (29.1% vs. 9.5%) compared with the comparative example, and it was statistically significant (p=0.042). Figure 8B The results showed that similar results could be obtained on human cells. The tumor cell killing ability of the embodiment increased by 5.9% (86.5% vs. 80.6%) compared with the comparative example, which confirmed that the dendritic cell tumor vaccine of the present invention can more effectively activate T cells.

[0094] In the experiment, brain tumor samples were taken from the orthotopic brain tumor model mice and immunofluorescence staining was performed to observe the CD4 + T cells and CD8 + T cell activation.

[0095] Please refer to 9A to 9F , CD4 + T cells and CD8 + The analysis results of T cell activation are shown in Figure 2. Fig. 9A The results of immunofluorescence staining are shown in Figure 2. Fig. 9B To identify CD4 + Quantitative analysis of T cell signals, Fig. 9C To calculate the infiltrating CD4 + The density of T cells, Fig.9D To immunofluorescence stain CD8 + Quantitative analysis of T cell signals, Fig.9E To calculate the infiltrating CD8 + The density of T cells, Fig.9F For CD4 + T cells and CD8 + Correlation analysis results of T cell density.

[0096] 9A to 9F The results showed that each tumor infiltrated with CD4 + T cells and CD8 + The total number of T cells showed a significant increase after treatment with the dendritic cell tumor vaccine of the present invention. + T cells and CD8 +The density of T cells also tends to increase after treatment with the dendritic cell tumor vaccine of the present invention, among which CD8 + The density of T cells increased strongly after treatment with the dendritic cell tumor vaccine of the present invention. After correlation analysis, the CD4 + T cells and CD8 + T cells have a positive correlation.

[0097] 3.4 Effect of the dendritic cell tumor vaccine of the present invention on the survival rate of mice with orthotopic melanoma model

[0098] In order to evaluate whether the dendritic cell tumor vaccine of the present invention has a better therapeutic effect on melanoma than the conventional dendritic cell tumor vaccine, the in situ melanoma model mice were randomly divided into groups and the following components were subcutaneously injected in the groin: PBS as an untreated control group, the dendritic cell tumor vaccine of the comparative example as a comparative example, and the dendritic cell tumor vaccine of the present invention as an example. After that, each group of in situ melanoma model mice was observed weekly with a living imaging system and measured with a ruler to draw a tumor growth curve. The death time of the in situ melanoma model mice was recorded and the Kaplan-Meier survival curve and the median survival were calculated.

[0099] Please refer to FIG. 10A to FIG. 10D , is a diagram showing the analysis of the therapeutic effect of the dendritic cell tumor vaccine of the present invention on in situ melanoma model mice, wherein Fig. 10A This is the in vivo image of the orthotopic melanoma model mouse on day 14. Fig. 10B The tumor growth curve is Fig. 10C This is a statistical chart of tumor size in orthotopic melanoma model mice on day 14. Fig. 10D The figure is a Kaplan-Meier survival curve. Please refer to Table 2 below, which is the median survival of the orthotopic melanoma model mice. The orthotopic melanoma model mice in the Example group are all alive and are represented by UD (Undetermined).

[0100] Table 2. Median survival of mice in the orthotopic melanoma model

[0101] Group Number (n) Median survival (days) Control Group 4 29.5 Comparative Example 4 34 Example 4 UD

[0102] FIG. 10A to FIG. 10DThe results in Table 2 show that the median survival of mice treated with two doses of the comparative dendritic cell tumor vaccine was extended by about 4.5 days (34 days vs. 29.5 days) compared to the untreated orthotopic melanoma model mice, and the tumor volume was smaller than that of the control group during the vaccine injection period (day 14) (p=0.0061). The orthotopic melanoma model mice treated with the dendritic cell tumor vaccine of the present invention survived for more than 5 weeks, and the tumor volume on day 14 was smaller than that of the comparative example (p=0.0134). B16F10Red-FLuc cells are very malignant tumor cells that grow rapidly in the orthotopic melanoma model mice. Without treatment, the tumor volume of the orthotopic melanoma model mice will exceed 1000mm between days 14 and 28. 3 The dendritic cell tumor vaccine of the present invention significantly suppressed tumor growth in the early stage of treatment, but still could not inhibit it in the later stage. After about the 28th day, the tumor volume in the in situ melanoma model mice exceeded 1000mm 3 .

[0103] 3.5 Effect of the dendritic cell tumor vaccine of the present invention on the survival rate of mice with in situ breast cancer model

[0104] In order to evaluate whether the dendritic cell tumor vaccine of the present invention has a better therapeutic effect on breast cancer than the conventional dendritic cell tumor vaccine, the in situ breast cancer model mice were randomly divided into groups and subcutaneously injected with the following components in the groin: PBS as a control group without treatment, a dendritic cell tumor vaccine of the comparative example as a comparative example, and the dendritic cell tumor vaccine of the present invention as an example. Afterwards, each group of in situ breast cancer model mice was observed weekly with a live imaging system and measured with a ruler, and a tumor growth curve was drawn.

[0105] Please refer to FIG. 11A to FIG. 11C , is a diagram showing the analysis of the therapeutic effect of the dendritic cell tumor vaccine of the present invention on an orthotopic breast cancer model mouse, wherein Fig.11A This is the in vivo image of the orthotopic breast cancer model mouse on day 35. Fig. 11B The tumor growth curve is Fig. 11C This is a statistical chart of tumor size on day 35 in mice with orthotopic breast cancer model.

[0106] FIG. 11A to FIG. 11CThe results showed that the tumor volume of the orthotopic breast cancer model mice treated with two doses of the comparative example dendritic cell tumor vaccine was still smaller than that of the control group on the 35th day, and the tumor volume of the orthotopic breast cancer model mice treated with the dendritic cell tumor vaccine of the present invention was smaller than that of the comparative example (p = 0.0176). Although E0771-Luc cells grow rapidly in the orthotopic breast cancer model mice, without treatment, the tumor volume of most orthotopic breast cancer model mice will exceed 10,000 mm after the 35th day. 3 Although the mice with orthotopic breast cancer model did not die, they had to be sacrificed for humanitarian reasons. However, the data from the orthotopic breast cancer model mice treated with the dendritic cell tumor vaccine of the present invention from day 35 to day 42 showed that the dendritic cell tumor vaccine of the present invention could continue to suppress tumor growth.

[0107] The above results demonstrate that in different tumor models, including brain tumor, melanoma and breast cancer, the dendritic cell tumor vaccine of the present invention can effectively inhibit tumor growth, prolong the survival time of tumor mice, and even eliminate tumors.

[0108] Please refer to Fig.12 , is a schematic diagram of the mechanism of action of the pharmaceutical composition for treating cancer of the present invention. Fig.12 It is shown that in the original tumor cells, the MSI1 protein has a higher expression level. Therefore, in the conventional dendritic cell tumor vaccine process, the radiation pressure causes a moderate degree of immunogenic cell death of tumor cells, and also makes the dendritic cells reach a moderate maturity. The method for preparing tumor antigens proposed by the present invention inhibits the expression of the MSI1 gene by an inhibition method before the tumor cells are treated with radiation, thereby reducing the action of the MSI1 protein, which can increase the production and release of damage-related pattern molecules in tumor cells, thereby increasing the degree of immunogenic cell death of tumor cells, and can also obtain a better degree of dendritic cell maturity, thereby making the prepared dendritic cell tumor vaccine have a better therapeutic effect, so that the pharmaceutical composition for treating cancer containing the dendritic cell tumor vaccine of the present invention is a very promising tumor treatment method.

[0109] Although the present invention has been disclosed in the above embodiments, it is not intended to limit the present invention. Anyone skilled in the art can make various changes and modifications without departing from the spirit and scope of the present invention. Therefore, the scope of protection of the present invention shall be determined by the scope defined by the attached claims.

Claims

1. A method for preparing a tumor antigen, characterized in that: Include: Providing a tumor tissue specimen, and performing primary separation and culture on the tumor tissue specimen to obtain a tumor cell; performing an inhibition step to inhibit the expression of the MSI1 gene of the tumor cell by an inhibition method to obtain a suppressed tumor cell; and A pressure treatment step is performed to treat the suppressed tumor cells with a pressure treatment method to increase the damage associated molecular patterns (damage associated molecular patterns, DAMP) gene is expressed in large amounts to obtain a tumor cell after stress treatment; and A cell lysis step is performed to treat the pressure-treated tumor cells by a cell disruption method to obtain a tumor antigen.

2. The method for preparing a tumor antigen according to claim 1, characterized in that: The inhibition method is to inhibit by a gene knockdown, a gene knockout, a chemical inhibitor or a combination thereof.

3. The method for preparing a tumor antigen according to claim 2, characterized in that: The gene inhibition method uses a short interfering RNA (siRNA) to inhibit the expression of the MSI1 gene of the tumor cell. The short interfering RNA is a sequence shown in SEQ ID NO: 1, a sequence shown in SEQ ID NO: 2, a sequence shown in SEQ ID NO: 3, a sequence shown in SEQ ID NO: 4, or a combination thereof.

4. The method for preparing a tumor antigen according to claim 1, characterized in that: The pressure treatment method is a radiation irradiation treatment, a UV irradiation treatment, an oxygen deficiency treatment, a chemotherapy drug treatment, a chemical agent treatment or a combination thereof.

5. The method for preparing a tumor antigen according to claim 4, characterized in that: When the stress treatment method is the radiation irradiation treatment, the radiation dose is 10 Gy to 30 Gy.

6. The method for preparing a tumor antigen according to claim 4, characterized in that: When the pressure treatment method is the UV irradiation treatment, the pressure is 100 J / cm 2 UVC radiation irradiated the tumor cells.

7. The method for preparing a tumor antigen according to claim 4, characterized in that: When the stress treatment method is the hypoxia treatment, the suppressed tumor cells are cultured under the condition of 1% oxygen content for 16 hours.

8. The method for preparing a tumor antigen according to claim 1, characterized in that: The damage-related pattern molecular genes include HMG family genes, HSP70 family genes, HSP90 family genes and S100 family genes.

9. The method for preparing a tumor antigen according to claim 1, characterized in that: The damage-related pattern molecule genes include HMGB1 gene, HMGB2 gene, HMGN1 gene, HSP90AA1 gene, HSP90AB1 gene, HSP90B1 gene, HSPA1B gene, HSPA5 gene, HSPA1A gene, S100A11 gene, S100A10 gene, S100A13 gene, S100A4 gene, S100A2 gene, BSG gene, TLR4 gene, CALR gene, SRA1 gene, LRP1 gene, BCL2 gene and IL1R1 gene.

10. The method for preparing a tumor antigen according to claim 1, characterized in that: The cell disruption method is a freeze-thaw disruption method, an osmotic pressure impact disruption method, a high-pressure homogenization disruption method, an oscillating bead beating disruption method, a high-speed stirring bead grinding disruption method or an ultrasonic disruption method.

11. A tumor antigen, characterized in that The tumor antigen is prepared by the method for preparing the tumor antigen according to any one of claims 1 to 10.

12. A method for preparing a dendritic cell tumor vaccine, characterized in that: Include: Providing the tumor antigen as claimed in claim 11; isolating a dendritic cell; and A co-culture step is performed to co-culture the dendritic cells with the tumor antigen to obtain a dendritic cell tumor vaccine.

13. The method for preparing a dendritic cell tumor vaccine according to claim 12, characterized in that: The dendritic cells are autologous dendritic cells.

14. The method for preparing a dendritic cell tumor vaccine according to claim 12, characterized in that: The dendritic cells are allogeneic dendritic cells.

15. A dendritic cell tumor vaccine, characterized in that: The dendritic cell tumor vaccine is prepared by the preparation method of the dendritic cell tumor vaccine as claimed in claim 12.

16. A pharmaceutical composition for treating cancer, characterized in that: Include: The dendritic cell tumor vaccine as claimed in claim 15; and A pharmaceutically acceptable carrier.

17. The pharmaceutical composition for treating cancer according to claim 16, characterized in that It also contains a T cell.

18. The pharmaceutical composition for treating cancer according to claim 16, characterized in that It also includes a chemotherapy drug, a targeted therapy drug, an antibody drug, an immunomodulator or a combination thereof.